Interlace Sews Up $20.5M Series C Round

Framingham, MA-based Interlace Medical, which develops medical devices for gynecologists, announced today it has raised $20.5 million in Series C funding. The round was led by Baird Venture Partners and HLM Venture Partners and included new investors Hambrecht & Quist Capital Management and Aperture Venture Partners. Previous backers New Leaf Venture Partners and Spray Venture Partners returned for this round as well. Interlace says the Series C funds will be used to initiate the commercialization of its MyoSure system, which is intended as a less invasive method of removing fibroids and polyps from the uterus.

Author: Roxanne Palmer

Roxanne Palmer is interning at Xconomy's Boston office this summer. She is currently pursuing a master's degree in science and medical Journalism at Boston University after graduating from Brown in 2008 with a degree in English. Her thesis was on Herman Melville's Civil War poetry. When not chronicling the ups and downs of Boston's tech industry, Roxanne enjoys drawing, swimming, and birdwatching. Follow her on Twitter at http://twitter.com/roxannedpalmer, or email her at [email protected]. View all posts by Roxanne Palmer